Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Feb 2;13(2):228.
doi: 10.3390/v13020228.

Injectable Antiretroviral Drugs: Back to the Future

Marco Berruti  1 , Niccolò Riccardi  2 , Diana Canetti  3   4 , Sergio Lo Caputo  5 , Lucia Taramasso  6 , Antonio Di Biagio  1   6
Affiliations
Review

Injectable Antiretroviral Drugs: Back to the Future

Marco Berruti et al. Viruses. .

Abstract

Current HIV treatment regimens provide sustained virologic suppression, at least partially restore the immune system and have limited side effects; however, they do not allow viral eradication and they are burdened by daily pill intake with a life-long commitment for the people living with HIV (PHIV). Injectable agents might represent a turning point in the care of PHIV, allowing less frequent administration of antiretroviral treatment (ART), more widespread use of pre-exposure prophylaxis (PrEP) and more stable drug levels in the blood, thus increasing the odds to get closer to end the HIV pandemic. The aim of this manuscript is to give a comprehensive review of injectable antiretrovirals that have been used in the past, which are available now, will be available in the future, and their role in the treatment of HIV infection.

Keywords: ART; HIV; PrEP; antiretroviral; injectable; treatment.

PubMed Disclaimer

Conflict of interest statement

All the authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Zidovudine.
Figure 2
Figure 2
Enfuvirtide.
Figure 3
Figure 3
Rilpivirine.
Figure 4
Figure 4
Cabotegravir.
Figure 5
Figure 5
Ibalizumab.
Figure 6
Figure 6
GS-6207.
Figure 7
Figure 7
Albuvitirde.
See this image and copyright information in PMC

References

    1. Gottlieb M.S., Schroff R., Schanker H.M., Weisman J.D., Fan P.T., Wolf R.A., Saxon A. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: Evidence of a new acquired cellular immunodeficiency. N. Engl. J. Med. 1981;305:1425–1431. doi: 10.1056/NEJM198112103052401. - DOI - PubMed
    1. Unaids Data. [(accessed on 30 June 2020)];2020 Available online: https://www.unaids.org/sites/default/files/media_asset/UNAIDS_FactSheet_....
    1. Barré-Sinoussi F., Ross A.L., Delfraissy J.-F. Past, present and future: 30 years of HIV research. Nat. Rev. Genet. 2013;11:877–883. doi: 10.1038/nrmicro3132. - DOI - PubMed
    1. Zachariah R., Van Damme W., Arendt V., Schmit J.C., Harries A.D. The HIV/AIDS epidemic in sub-Saharan Africa: Thinking ahead on programmatic tasks and related operational research. J. Int. AIDS Soc. 2011;14:S7. doi: 10.1186/1758-2652-14-S1-S7. - DOI - PMC - PubMed
    1. Bain L.E., Nkoke C., Noubiap J.J.N. UNAIDS 90-90-90 targets to end the AIDS epidemic by 2020 are not realistic: Comment on “Can the UNAIDS 90-90-90 target be achieved? A systematic analysis of national HIV treatment cascades”. BMJ Glob. Health. 2017;2:e000227. doi: 10.1136/bmjgh-2016-000227. - DOI - PMC - PubMed

MeSH terms

Substances

LinkOut - more resources